Navigation Links
Freezing Stage for Microtome, 38 mm x 38 mm, 220V

ProductsFreezing Stage for Microtome, 38 mm x 38 mm, 220V
Company myNeuroLab.com
Item Freezing Stage for Microtome, 38 mm x 38 mm, 220V
Features Inquire
Description MNL 4404 & 4405 series Freezing Stages fit easily onto most microtomes. These thermoelectric devices have no moving parts and need only the AC supply and a trickle of running water for operation. Freezing starts immediately and can be maintained indefinitely. Stage temperature is adjustable so that optimum cutting temperatures can be set for different kinds of tissue. Our Freezing Stages are especially valuable for multiple sectioning of brains and other organs which are too large for cryostats. Stages can also be used to control the temperature of materials other than tissue and have been used in research on integrated circuits, photo diodes, liquid crystals, wax formation on fuel oils and even freezing concrete. Temperature control is automatic and can be maintained to 0.1 degree C. A sensor mounted in the stage provides temperature monitoring for control purposes. Temperature range is -35 degree to +60 degree C. Controller can be used as an independent thermometer and a microprobe is supplied for this purpose. All water tubes are self sealing. All stages require running water for operating. If a tap is not conveniently available in the lab, a circulating pump and tank can be used. Have you checked outVibratomes Sliding Microtomes?
Info myNeuroLab.com
Customer Service: (866) 444-0944

Related medicine products :

1. Freezing Stage for Microtome, 38 mm x 38 mm
2. Freezing Stage for Microtome, 76.2 mm x 79.4 mm
3. Freezing Stage for Microtome, 76.2mmx79.4mm, 220V
4. Cryostage Freezing Stage, 220V
5. Cryostage Freezing Stage, 110V
6. Solid State Freezer/Cooling Stage, 110v, 30 x 30mm
7. Solid State Freezer/Cooling Stage, 110V, 40 x 40mm
8. Solid State Freezer/Cooling Stage, 220V, 30 x 30mm
9. Solid State Freezer/Cooling Stage, 220V, 40 x 40mm
10. Rotating Stage Assembly
11. Two Stage Seed Needle
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products:
(Date:12/4/2009)... , , PEMBROKE, Bermuda, Dec. 4 /PRN...ny Holdings, Ltd (NYSE: AWH ) today announced th...Officer, and Jack Sennott, Executive Vice,Presiden...esenting at the 2009,Goldman Sachs U.S. Financial ...s Conference Center in New York City on Tuesday, D...
(Date:12/4/2009)... , , MADISON HEIGHTS, Mich., Dec...urities Review Committee of BetterInvesting Magaz... ) as its February 2010 "Stock to Study" and C.R....Undervalued Stock" for investors, informational an...rgan because of growth opportunities involving its...
(Date:12/4/2009)... , Late recurrence is a risk for some pediatric c...the central nervous system, according to a new stu...the National Cancer Institute . , This study was...ate recurrence (after 5 years and up to 20 years) ...i-Masker, M.D., of the Aflac Cancer Center and Blo...
(Date:12/4/2009)... , More than 15 million Americans are recruited...ing to the Alliance for Human Research Protection ...ticipation. , Research institutions view pay...xpenses; not as compensation for potential risks r... new study finds that volunteers have a very diffe...
(Date:12/4/2009)... Increasing exercise, water and fruit consumptio...IDAY, Dec. 4 (HealthDay News) -- Increased exercis...among the most effective weight control strategies...ers surveyed 130 adolescents about their weight-co...ad succeeded in losing weight and 68 had not. The ...
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2
...genital Heart Disease published recently in the Eu...ty of adult heart care and the extent of its defic...improvement in the treatment of pediatric heart di...of the patients and list the deficient areas. 71 c...
... by researchers at Columbia University Medical Cen... rates and adherence to cancer treatment, //it has...had stopped their chemotherapy. More specifically,...efore completion. Non-compliance rates in th...
...rs at University of Manchester now reveals that sp...iseases, Vascular Dementia and Alzheimer's disease...sh Medical Journal (BMJ). This finding could e...d vascular dementia can account for a major propor...
...n 2004 the sales of Celebrex was $3.3 billion worl...g causing heart attacks the company stopped advert...he consumer ad market in hopes of reviving sales o...oost it sales. Each ad includes a boldface warnin...
...quently among children. It is one of the diseases ...ow 3 months of age//. Hence Dr. Lawrence S. Eichen...an Diego and colleagues came up with the fluticaso...en compared to ointments and creams. It is very he...
...ssion of senile amyloidosis to offspring from affe...om mother to child// have been raised. Details abo...is in offspring of mice with AApoAII amyloidosis,'...including amyloidosis. Amyloidosis occurs when cel...
Other Medicine News:Health News:Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy 2Health News:Doubts About In UteroTransmission Of Senile Amyloidosis 2
(Date:12/3/2009)...DOYLESTOWN, Pa., Dec. 3 ...ation, (Nasdaq: QGLY ) www.quigleyco.com announ...ation of its opportunities to develop prescription... that it is in its best interests to focus primari... include but are not limited to its Cold-EEZE®...
(Date:12/3/2009)..., WARRENDALE, Pa., Dec. 3 Radiol... injection-record integration capabilities at the ...n Chicago. The Connect.PACS(TM) product, enabli... its kind, is the latest release in the company,s ... ,, (Photo: http://www.newscom.com/cgi-bin/...
(Date:12/3/2009)..., HOERSHOLM, Denmark and SAN DIEGO, Californi... Successfully Inhibits miR-122, a microRNA Importa...ificantly Reducing Hepatitis C,Virus in the Bloods...,Hepatitis C Virus , - SPC3649 Demonstrat...nd,No Serious Adverse Events in the Treated Animal...
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 1Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 2Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 3Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 4Genes May Raise Risk of Neuroblastoma in Kids 49265 1Genes May Raise Risk of Neuroblastoma in Kids 49265 2Genes May Raise Risk of Neuroblastoma in Kids 49265 3Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 1Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 2